Bioventus Inc (OQ:BVS)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Tel: N/A
IR: See website
Key People
Robert E. Claypoole
President, Chief Executive Officer, Director
Mark Singleton
Chief Financial Officer, Senior Vice President
Katrina Church
Senior Vice President, Chief Compliance Officer
Anthony D'adamio
Senior Vice President, General Counsel
Sharon W. Klugewicz
Senior Vice President - Quality and Regulatory Affairs
Business Overview
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body's natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
Financial Overview
For the three months ended 30 March 2024, Bioventus Inc revenues increased 9% to $129.5M. Net loss before extraordinary items decreased 94% to $4.6M. Revenues reflect U.S. segment increase of 10% to $114.3M, International segment increase of 1% to $15.2M. Lower net loss reflects Impairment of assets decrease from $78.6M (expense) to $0K, Selling, general ane expe decrease of 4% to $75.8M (expense).
Employees: 995 as of Mar 30, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $874.01M as of Mar 30, 2024
Annual revenue (TTM): $522.74M as of Mar 30, 2024
EBITDA (TTM): $94.31M as of Mar 30, 2024
Net annual income (TTM): -$21.65M as of Mar 30, 2024
Free cash flow (TTM): $2.76M as of Mar 30, 2024
Net Debt Last Fiscal Year: $366.07M as of Mar 30, 2024
Shares outstanding: 79,614,354 as of Apr 30, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.